留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

基于术前血清学指标AFP和GGT的标准在预测肝细胞癌患者肝移植术后长期生存中的作用研究

严成, 陈新国, 金海龙, 等. 基于术前血清学指标AFP和GGT的标准在预测肝细胞癌患者肝移植术后长期生存中的作用研究[J]. 器官移植, 2023, 14(2): 248-256. doi: 10.3969/j.issn.1674-7445.2023.02.011
引用本文: 严成, 陈新国, 金海龙, 等. 基于术前血清学指标AFP和GGT的标准在预测肝细胞癌患者肝移植术后长期生存中的作用研究[J]. 器官移植, 2023, 14(2): 248-256. doi: 10.3969/j.issn.1674-7445.2023.02.011
Yan Cheng, Chen Xinguo, Jin Hailong, et al. Role of the criteria based on preoperative serological indexes of AFP and GGT in predicting long-term survival of patients with hepatocellular carcinoma after liver transplantation[J]. ORGAN TRANSPLANTATION, 2023, 14(2): 248-256. doi: 10.3969/j.issn.1674-7445.2023.02.011
Citation: Yan Cheng, Chen Xinguo, Jin Hailong, et al. Role of the criteria based on preoperative serological indexes of AFP and GGT in predicting long-term survival of patients with hepatocellular carcinoma after liver transplantation[J]. ORGAN TRANSPLANTATION, 2023, 14(2): 248-256. doi: 10.3969/j.issn.1674-7445.2023.02.011

基于术前血清学指标AFP和GGT的标准在预测肝细胞癌患者肝移植术后长期生存中的作用研究

doi: 10.3969/j.issn.1674-7445.2023.02.011
基金项目: 

国家自然科学基金项目 81372595

详细信息
    作者简介:
    通讯作者:

    张庆,博士,主任医师,研究方向为肝癌肝移植,Email:zqy6920@sina.com

  • 中图分类号: R617, R735.7

Role of the criteria based on preoperative serological indexes of AFP and GGT in predicting long-term survival of patients with hepatocellular carcinoma after liver transplantation

More Information
  • 摘要:   目的  分析术前血清学指标对肝细胞癌(HCC)患者肝移植术后长期生存和肿瘤复发的预测作用,探索其对扩大米兰标准的意义。  方法  回顾性分析669例HCC肝移植受者的临床资料,采用受试者工作特征(ROC)曲线计算最佳截取值,采用单因素和多因素回归分析影响HCC患者肝移植术后总生存率和无复发生存率的危险因素,分析术前血清肝酶与肿瘤病理学特征的相关性,比较甲胎蛋白(AFP)联合γ-谷氨酰转移酶(GGT)以及不同肝移植标准对HCC患者肝移植术后生存和复发的预测价值。  结果  超米兰标准、肿瘤直径之和(TTD) > 8 cm、AFP > 200 ng/mL和GGT > 84 U/L是影响HCC患者肝移植术后总生存率和无复发生存率的独立危险因素(均为P < 0.05)。相关性分析结果显示,术前血清GGT水平与TTD,肿瘤数量,静脉侵犯,微卫星病变,包膜侵犯,肿瘤、淋巴结、转移(TNM)分期,Child-Pugh评分,超米兰标准均存在相关性(均为P < 0.05)。将米兰标准、TTD与血清肝酶指标(AFP和GGT)结合,提出Milan-AFP-GGT-TTD(M-AGT)标准。符合M-AGT标准者(其中111例超米兰标准)术后5年总生存率和无复发生存率均高于符合杭州标准者(均为P < 0.05),与符合加州大学旧金山分校(UCSF)标准者的术后5年总生存率和无复发生存率比较差异均无统计学意义(均为P > 0.05)。  结论  术前血清学指标AFP和GGT可有效预测HCC患者肝移植术后长期生存和肿瘤复发,建立基于血清学指标的M-AGT标准有助于补充米兰标准,且简单易行。

     

  • 图  1  术前血清GGT、AST、ALT和AFP的最佳截取值

    Figure  1.  The optimal cut-off values for preoperative serum GGT, AST, ALT and AFP

    图  2  AFP联合GGT的生存曲线

    Figure  2.  Survival curves of AFP combined with GGT

    图  3  M-AGT标准的生存曲线

    Figure  3.  Survival curves for M-AGT criteria

    图  4  M-AGT标准和杭州标准的生存曲线比较

    Figure  4.  Comparison of survival curves between M-AGT criteria and Hangzhou criteria

    图  5  不同肝移植标准术后5年总生存率和无复发生存率的ROC曲线

    Figure  5.  ROC curves for the 5-year overall survival and recurrence-free survival rates of different criteria after liver transplantation

    表  1  肝移植术后生存和复发危险因素的单因素分析

    Table  1.   Univariate analysis of risk factors for survival and recurrence after liver transplantation

    变量 n 总生存率(%) P 无复发生存率(%) P
    1年 3年 5年 7年 1年 3年 5年 7年
    性别 0.233 0.227
      男 618 88 72 68 65 77 66 63 62
      女 51 90 80 80 77 78 76 76 73
    年龄 0.566 0.770
       < 40岁 81 87 78 73 68 83 72 69 64
      40~49岁 246 88 68 65 64 75 65 62 62
      50~59岁 247 88 74 70 66 78 67 64 62
       > 60岁 95 86 76 73 70 76 69 68 68
    GGT < 0.001 < 0.001
      ≤84 U/L 371 92 85 82 81 87 81 78 78
       > 84 U/L 298 82 57 53 48 64 50 47 45
    AST < 0.001 < 0.001
      ≤63 U/L 402 92 82 80 77 84 76 74 74
       > 63 U/L 267 82 60 54 51 66 55 50 48
    ALT < 0.001 < 0.001
      ≤56 U/L 414 90 79 77 75 82 74 72 72
       > 56 U/L 255 85 63 56 52 69 57 52 50
    AFP < 0.001 < 0.001
      ≤200 ng/mL 470 91 80 78 75 85 76 74 72
       > 200 ng/mL 199 80 54 46 43 58 46 41 40
    HBV DNA 0.225 0.525
      ≤1 copies/mL 460 88 71 66 65 77 66 63 62
       > 1 copies/mL 209 88 76 74 69 78 69 67 65
    微卫星病变 0.002 0.001
      否 466 89 76 73 70 80 71 68 67
      是 203 85 65 58 56 69 58 55 53
    静脉侵犯 < 0.001 < 0.001
      否 582 90 78 74 71 81 72 69 68
      是 87 73 39 37 33 50 33 33 30
    包膜侵犯 0.143 0.034
      否 574 88 74 71 68 78 69 66 65
      是 95 87 64 57 57 69 55 55 55
    TNM分期 < 0.001 < 0.001
      1 307 90 81 77 75 85 77 73 72
      2 191 90 71 68 67 77 64 62 61
      3 129 81 56 52 43 59 51 47 45
      4~6 42 85 69 65 65 73 62 62 62
    Child-Pugh评分 0.649 0.491
      ≤6分 306 88 73 69 64 78 65 63 61
      7~9分 223 89 75 70 70 78 71 68 67
       > 9分 140 86 70 66 65 74 65 62 62
    MELD评分 0.094 0.202
      ≤15分 507 89 74 71 67 78 68 66 64
       > 15分 162 85 69 64 63 75 64 61 60
    肿瘤数目 < 0.001 < 0.001
      单个 398 91 79 77 74 84 76 73 72
      多个 271 84 63 57 54 67 54 51 51
    TTD < 0.001 < 0.001
      ≤8 cm 541 92 81 78 75 84 76 73 72
       > 8 cm 128 72 38 33 28 46 31 29 27
    组织学分化 0.526 0.305
      高 30 87 80 76 70 77 66 66 66
      中 558 89 73 69 66 78 68 65 64
      低 81 84 67 65 65 68 60 58 58
    米兰标准 < 0.001 < 0.001
      符合 357 95 91 89 87 91 87 85 84
      不符合 312 80 52 45 42 61 45 41 40
    杭州标准 < 0.001 < 0.001
      符合 605 90 78 75 72 82 73 70 68
      不符合 64 65 20 16 16 28 13 13 13
    UCSF标准 < 0.001 < 0.001
      符合 398 94 90 87 85 90 85 83 82
      不符合 271 79 48 42 38 59 41 37 35
    下载: 导出CSV

    表  2  HCC肝移植术后总生存率危险因素的多因素分析

    Table  2.   Multivariate analysis of the risk factors for overall survival rate after liver transplantation for HCC

    变量 回归系数 标准误 Wald χ2 HR 95% CI P
    超米兰标准 1.277 0.198 41.566 3.585 2.432~5.286 < 0.001
    TTD > 8 cm 0.559 0.158 12.609 1.749 1.285~2.382 < 0.001
    AFP > 200 ng/mL 0.478 0.147 10.600 1.613 1.210~2.152 0.001
    GGT > 84 U/L 0.473 0.161 8.583 1.605 1.170~2.202 0.003
    AST > 63 U/L 0.561 0.149 14.209 1.753 1.309~2.347 < 0.001
    注:① HR为风险比。
    CI为可信区间。
    下载: 导出CSV

    表  3  HCC肝移植术后无复发生存率危险因素的多因素分析

    Table  3.   Multivariate analysis of the risk factors for recurrence-free survival rate after liver transplantation for HCC

    变量 回归系数 标准误 Wald χ2 HR 95%CI P
    超米兰标准 1.125 0.177 40.201 3.080 2.175~4.361 < 0.001
    TTD > 8 cm 0.564 0.151 14.010 1.758 1.308~2.362 < 0.001
    AFP > 200 ng/mL 0.616 0.137 20.372 1.852 1.417~2.420 < 0.001
    GGT > 84 U/L 0.511 0.152 11.357 1.667 1.238~2.245 0.001
    ALT > 56 U/L 0.365 0.135 7.326 1.441 1.106~1.877 0.007
    注:① HR为风险比。
    CI为可信区间。
    下载: 导出CSV

    表  4  超米兰标准患者中不同肝移植标准的总生存率和无复发生存率比较

    Table  4.   Comparison of overall survival and recurrence-free survival rates of different liver transplant criteria in patients exceeded Milan criteria

    肝移植标准名称 n 总生存率(%) P 无复发生存率(%) P
    1年 3年 5年 7年 1年 3年 5年 7年
    M-AGT标准 111 85 71 64 61 74 63 58 58
    杭州标准 249 84 60 53 49 0.075 69 53 48 46 0.092
    UCSF标准 65 88 81 71 68 0.315 78 72 68 65 0.327
    下载: 导出CSV
  • [1] SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
    [2] CAO W, CHEN HD, YU YW, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020[J]. Chin Med J (Engl), 2021, 134(7): 783-791. DOI: 10.1097/CM9.0000000000001474.
    [3] INCE V, SAHIN TT, AKBULUT S, et al. Liver transplantation for hepatocellular carcinoma: historical evolution of transplantation criteria[J]. World J Clin Cases, 2022, 10(29): 10413-10427. DOI: 10.12998/wjcc.v10.i29.10413.
    [4] SAPISOCHIN G, BRUIX J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches[J]. Nat Rev Gastroenterol Hepatol, 2017, 14(4): 203-217. DOI: 10.1038/nrgastro.2016.193.
    [5] XU X, LU D, LING Q, et al. Liver transplantation for hepatocellular carcinoma beyond the Milan criteria[J]. Gut, 2016, 65(6): 1035-1041. DOI: 10.1136/gutjnl-2014-308513.
    [6] TONIUTTO P, FUMOLO E, FORNASIERE E, et al. Liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a comprehensive review[J]. J Clin Med, 2021, 10(17): 3932. DOI: 10.3390/jcm10173932.
    [7] AKBULUT S, KOC C. Do we need to be limited by matching Milan criteria for survival in living donor liver transplantation?[J]. J Gastrointest Cancer, 2020, 51(4): 1107-1113. DOI: 10.1007/s12029-020-00482-0.
    [8] LINGIAH V A, NIAZI M, OLIVO R, et al. Liver transplantation beyond Milan criteria[J]. J Clin Transl Hepatol, 2020, 8(1): 69-75. DOI: 10.14218/JCTH.2019.00050.
    [9] TONIUTTO P, FORNASIERE E, FUMOLO E, et al. Risk factors for hepatocellular carcinoma recurrence after liver transplantation[J]. Hepatoma Res, 2020, 6(8): 46-66. DOI: 10.20517/2394-5079.2020.40.
    [10] NOTARPAOLO A, LAYESE R, MAGISTRI P, et al. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC[J]. J Hepatol, 2017, 66(3): 552-559. DOI: 10.1016/j.jhep.2016.10.038.
    [11] ZHANG LX, LV Y, XU AM, et al. The prognostic significance of serum gamma-glutamyltransferase levels and AST/ALT in primary hepatic carcinoma[J]. BMC Cancer, 2019, 19(1): 841. DOI: 10.1186/s12885-019-6011-8.
    [12] LI ZC, LI Z, LI C, et al. Letter: elevated aspartate aminotransferase and aspartate aminotransferase to alanine aminotransferase ratio predicts poor survival in hepatocellular carcinoma after resection[J]. Aliment Pharmacol Ther, 2020, 52(11/12): 1762-1763. DOI: 10.1111/apt.16124.
    [13] GUO C, LIANG H, YUAN W, et al. Analysis on the value of soluble intercellular adhesion molecule-1 (sICAM-1), alpha fetoprotein (AFP), and aspartate aminotransferase/platelet ratio index (APRI) in predicting the prognostic survival of patients with primary liver cancer after radiofrequency ablation[J]. Ann Palliat Med, 2021, 10(4): 4760-4767. DOI: 10.21037/apm-21-749.
    [14] ALIM A, ERDOGAN Y, DAYANGAC M, et al. Living donor liver transplantation: the optimal curative treatment for hepatocellular carcinoma even beyond Milan criteria[J]. Cancer Control, 2021, 28: 10732748211011960. DOI: 10.1177/10732748211011960.
    [15] XU DW, WAN P, XIA Q. Liver transplantation for hepatocellular carcinoma beyond the Milan criteria: a review[J]. World J Gastroenterol, 2016, 22(12): 3325-3334. DOI: 10.3748/wjg.v22.i12.3325.
    [16] 方海星, 鲁迪, 卓建勇, 等. 肝癌肝移植杭州标准应用于肝癌切除术预后的评价[J]. 中华普通外科杂志, 2018, 33(11): 904-906. DOI: 10.3760/cma.j.issn.1007-631X.2018.11.003.

    FANG HX, LU D, ZHUO JY, et al. Prognostic evaluation of candidate selection Hangzhou criteria of hepatocellular carcinoma for liver transplantation after hepatectomy[J]. Chin J Gen Surg, 2018, 33(11): 904-906. DOI: 10.3760/cma.j.issn.1007-631X.2018.11.003.
    [17] INCE V, AKBULUT S, OTAN E, et al. Liver transplantation for hepatocellular carcinoma: malatya experience and proposals for expanded criteria[J]. J Gastrointest Cancer, 2020, 51(3): 998-1005. DOI: 10.1007/s12029-020-00424-w.
    [18] RANGWANI S, ARDESHNA D R, MUMTAZ K, et al. Update on endoscopic ultrasound-guided liver biopsy[J]. World J Gastroenterol, 2022, 28(28): 3586-3594. DOI: 10.3748/wjg.v28.i28.3586.
    [19] KHALIFA A, ROCKEY D C. The utility of liver biopsy in 2020[J]. Curr Opin Gastroenterol, 2020, 36(3): 184-191. DOI: 10.1097/MOG.0000000000000621.
    [20] CORTI A, BELCASTRO E, DOMINICI S, et al. The dark side of gamma-glutamyltransferase (GGT): pathogenic effects of an 'antioxidant' enzyme[J]. Free Radic Biol Med, 2020, 160: 807-819. DOI: 10.1016/j.freeradbiomed.2020.09.005.
    [21] ZHANG Q, JIAO X. LDH and GGT/ALT ratio as novel prognostic biomarkers in hepatocellular carcinoma patients after liver transplantation[J]. Comput Math Methods Med, 2021: 9809990. DOI: 10.1155/2021/9809990.
    [22] FU SJ, ZHAO Q, JI F, et al. Elevated preoperative serum gamma-glutamyltranspeptidase predicts poor prognosis for hepatocellular carcinoma after liver transplantation[J]. Sci Rep, 2016, 6: 28835. DOI: 10.1038/srep28835.
    [23] FU S, GUO Z, LI S, et al. Prognostic value of preoperative serum gamma-glutamyltranspeptidase in patients with hepatocellular carcinoma after hepatectomy[J]. Tumour biol, 2016, 37(3): 3433-3440. DOI: 10.1007/s13277-015-4136-1.
    [24] MA H, ZHANG L, TANG B, et al. gamma-glutamyltranspeptidase is a prognostic marker of survival and recurrence in radiofrequency-ablation treatment of hepatocellular carcinoma[J]. Ann Surg Oncol, 2014, 21(9): 3084-3089. DOI: 10.1245/s10434-014-3724-4.
    [25] LI JH, CHEN T, XING H, et al. The AGH score is a predictor of disease-free survival and targeted therapy efficacy after liver transplantation in patients with hepatocellular carcinoma[J]. Hepatobiliary Pancreat Dis Int, 2022, DOI: 10.1016/j.hbpd.2022.04.003[Epubaheadofprint].
    [26] ÖZDEMIR F, BASKIRAN A. The importance of AFP in liver transplantation for HCC[J]. J Gastrointest Cancer, 2020, 51(4): 1127-1132. DOI: 10.1007/s12029-020-00486-w.
    [27] KOCH C, BETTE T, WAIDMANN O, et al. AFP ratio predicts HCC recurrence after liver transplantation[J]. PLoS One, 2020, 15(7): e0235576. DOI: 10.1371/journal.pone.0235576.
    [28] SCHLOSSER S, TÜMEN D, VOLZ B, et al. HCC biomarkers - state of the old and outlook to future promising biomarkers and their potential in everyday clinical practice[J]. Front Oncol, 2022, 12: 1016952. DOI: 10.3389/fonc.2022.1016952.
    [29] RUCH B, WAGLER J, KUMM K, et al. Hepatocellular carcinoma, alpha fetoprotein, and liver allocation for transplantation: past, present and future[J]. Curr Oncol, 2022, 29(10): 7537-7551. DOI: 10.3390/curroncol29100593.
    [30] ZHANG DL, FENG DN, HE X, et al. The combination of AFP and "Up-to-seven" criteria may be a better strategy for liver transplantation in Chinese cirrhotic HCC patients[J]. Front Oncol, 2022, 12: 959151. DOI: 10.3389/fonc.2022.959151.
    [31] MAZZAFERRO V, SPOSITO C, ZHOU J, et al. Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma[J]. Gastroenterology, 2018, 154(1): 128-139. DOI: 10.1053/j.gastro.2017.09.025.
    [32] PAVEL MC, FUSTER J. Expansion of the hepatocellular carcinoma Milan criteria in liver transplantation: future directions[J]. World J Gastroenterol, 2018, 24(32): 3626-3636. DOI: 10.3748/wjg.v24.i32.3626.
    [33] YAO FY, FERRELL L, BASS NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival[J]. Hepatology, 2001, 33(6): 1394-1403. DOI: 10.1053/jhep.2001.24563.
    [34] LIANG HR, HSIEH CE, LIN KH, et al. Living donor liver transplantation for hepatocellular carcinoma beyond the Milan criteria: outcome of expanded criteria in tumor size[J]. BMC Surg, 2021, 21(1): 401. DOI: 10.1186/s12893-021-01403-z.
    [35] INCE V, ARA C, YILMAZ S. Malatya and other criteria for liver transplantation in hepatocellular carcinoma[J]. J Gastrointest Cancer, 2020, 51(4): 1118-1121. DOI: 10.1007/s12029-020-00484-y.
  • 加载中
图(6) / 表(4)
计量
  • 文章访问数:  220
  • HTML全文浏览量:  70
  • PDF下载量:  68
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-10-18
  • 网络出版日期:  2023-03-15
  • 刊出日期:  2023-03-15

目录

    /

    返回文章
    返回